The PD-1–TREM2 scFv suppressed PD-1/PD-L1 signaling and exhibited extended intratumoral persistence, indicating that PD-1–TREM2 scFv CAR-T-cell-based ACT represents a promising therapeutic avenue for CRC [170]. Here, PDCD1 is linked to colorectal carcinoma.